Anaphylactic Reaction to Pemetrexed: A Case Report
Pemetrexed is approved to treat non-small cell lung cancer and has an overall favorable toxicity profile. We describe a 58-year-old man who developped an anaphylactic shock within few minutes from the beginning of pemetrexed perfusion. Pemetrexed was discontinued and the patient’s symptoms graduall...
Main Authors: | Heloise Capelle, Joelle Birnbaum, Pascale Tomasini, Céline Tummino, Marion Gouitaa, Nathalie Ausias, Denis Charpin, Fabrice Barlesi, Marc Montana |
---|---|
Format: | Article |
Language: | English |
Published: |
Canadian Society for Pharmaceutical Sciences
2014-05-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/21453 |
Similar Items
-
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes
by: Pascale Tomasini, et al.
Published: (2016-05-01) -
Why is the prevalence of allergic diseases increasing? A critical assessment of some classical risk factors
by: Denis Charpin, et al.
Published: (2001-01-01) -
Anaphylactic reactions in anesthetic agents
by: Evangelina Dávila Cabo de Villa
Published: (2019-04-01) -
Anaphylactic Reaction to Camomile Tea
by: Christian Andres, et al.
Published: (2009-01-01) -
Anaphylactic reactions in anesthetic agents
by: Evangelina Dávila Cabo de Villa
Published: (2019-04-01)